lunes, 24 de marzo de 2014

WHO Pharmaceuticals Newsletter N1 2014



Regulatory Matters
Acetaminophen (Paracetamol INN) ............................. 4
Acipimox ................................................................ 4
Capecitabine ........................................................... 5
Clobazam ................................................................ 5
Duloxetine ---............................................................ 5
Finasteride and dutasteride ...................................... 6
Methylphenidate ...................................................... 6
Ofatumumab ............................................................ 7
Prasugrel ................................................................ 7
Recombinant interferon-beta ..................................... 8
Regadenoson and adenosine ..................................... 8
Rituximab ................................................................ 8
Rosiglitazone ............................................................ 8
Sodium Phosphate Over-the-Counter Products .............. 9
Strontium ranelate .................................................... 9
Temozolomide .......................................................... 10
Lenalidomide ........................................................... 10
Zolpidem tartrate ..................................................... 10

Safety of medicines
Clopidogrel ............................................................. 12
Minocycline ............................................................. 12
Pioglitazone ............................................................. 12
Ponatinib ................................................................. 13

 Signal
Emtricitabine/Efavirenz/Tenofovir Disoproxil Fumarate and Phosphatase
Alkaline Increased ................................................... 14
Ibuprofen and Erectile Dysfunction ............................ 18
Parathyroid Hormone and Myocardial Ischaemia ......... 21
Roflumilast and Pancreatitis .................................... 26
Vemurafenib and Granulocytopenia........................... 30
The UMC Measures of Disproportionate Reporting .... 34
Feature
Recommendations from the Thirty-sixth Annual Meeting of National
Pharmacovigilance Centres ..................................... 36